Cybin Completes FDA Type B Initial Breakthrough Therapy Meeting; Plans For CYB003 Phase 3 Program In Major Depressive Disorder, Expects To Initiate Phase 3 In Late Summer
Portfolio Pulse from Benzinga Newsdesk
Cybin has completed an FDA Type B initial breakthrough therapy meeting and plans to initiate a Phase 3 program for CYB003 in treating major depressive disorder by late summer.
August 13, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin has completed an FDA Type B initial breakthrough therapy meeting and plans to initiate a Phase 3 program for CYB003 in treating major depressive disorder by late summer.
The completion of the FDA Type B meeting and the planned initiation of Phase 3 trials for CYB003 are significant milestones. This progress could positively impact Cybin's stock price as it moves closer to potentially bringing a new treatment for major depressive disorder to market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100